TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.<b>Clinical Trial Registration:</b> NCT04713514 (ClinicalTrials.gov).
Authors
- Laurence Gladieff (ORCID: https://orcid.org/0000-0002-6980-9719)
- Frederik Marmé (ORCID: https://orcid.org/0000-0002-6591-3367)
- Renaud Sabatier (ORCID: https://orcid.org/0000-0002-5821-682X)
- Olivier Trédan (ORCID: https://orcid.org/0000-0001-5881-9383)
- Alexandra Léary (ORCID: https://orcid.org/0000-0002-2043-2244)
- Jean‐Sébastien Frenel (ORCID: https://orcid.org/0000-0002-5273-0561)
- Antoine Angelergues (ORCID: https://orcid.org/0009-0005-4876-918X)
- Thomas Grellety (ORCID: https://orcid.org/0000-0001-5316-1420)
- Coriolan Lebreton (ORCID: https://orcid.org/0000-0002-4275-1721)
- Emilie Kaczmarek (ORCID: https://orcid.org/0000-0002-2633-3773)
- Toon Van Gorp (ORCID: https://orcid.org/0000-0002-2564-721X)
- Rayan Kabirian (ORCID: https://orcid.org/0000-0001-5165-9743)
- Thibault De La Motte Rouge (ORCID: https://orcid.org/0000-0002-0088-6003)
- Michel Fabbro (ORCID: https://orcid.org/0000-0003-1910-4777)
- Julia Welz (ORCID: https://orcid.org/0000-0003-0102-6053)
- Xavier Paolettí (ORCID: https://orcid.org/0000-0002-1250-0040)
- Lauriane Eberst (ORCID: https://orcid.org/0000-0003-0973-5954)
- Laura Mansi (ORCID: https://orcid.org/0000-0001-6079-5085)
- Jérôme Alexandre (ORCID: https://orcid.org/0000-0001-5252-5800)
- Laure Favier
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Heidelberg University (DE)
- Institut Gustave Roussy (FR)
- University Hospital Heidelberg (DE)
- Institut de Cancérologie Strasbourg (FR)
- Hôpital Cochin (FR)
- Centre Georges François Leclerc (FR)
- Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (DE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Centre Eugène Marquis (FR)
- Groupe Hospitalier Diaconesses Croix Saint-Simon (FR)
- Centre Hospitalier de la Côte Basque (FR)
- Institut Claudius Regaud (FR)
- Centre Oscar Lambret (FR)
- Institut Bergonié (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Kliniken Essen-Mitte (DE)
- Institut Paoli-Calmettes (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1080/14796694.2024.2386922
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00